



Current Topics in Contraception

Alexandra Herman, PharmD
asible@salud.unm.edu

Assistant Professor – Clinical Educator
 University of New Mexico College of Pharmacy
 NMPHA Mid-Winter Meeting
 January 24, 2021

1

Objectives

- **The pharmacist participant will be able to:**
 - List the principles of reproductive justice.
 - Discuss recent FDA approvals of new and emerging hormonal and non-hormonal contraceptive options.
 - Given a patient case, describe how to engage in shared decision-making with a patient about contraceptive options.
- **The pharmacy technician participant will be able to:**
 - List the principles of reproductive justice.
 - Discuss recent FDA approvals of new and emerging hormonal and non-hormonal contraceptive options.
 - Refer patients for pharmacist counseling on contraceptive choices and management.

2

Reproductive Justice

The human right to...

- maintain bodily autonomy
- have children
- not have children
- parent the children we have in safe & sustainable communities

For more information:

<https://www.sistersong.net/reproductive-justice>



3

Reproductive Justice

How can we apply this to contraception discussions in the pharmacy?

- Avoid making assumptions and judgments about patients' plans to have or not have children
- Counsel on all available contraceptive methods
- Avoid coercing/pressuring patients into choosing certain methods

4

Contraception Management

- Nearly half of U.S. pregnancies are described as "unintended" (wanted later or never)
- 54% of unintended pregnancies occur in patients who **did not use** a contraceptive method
- 41% of unintended pregnancies occur in patients who **Inconsistently used** a contraceptive method
- 5% of unintended pregnancies in patients who consistently used a contraceptive method



Source: Guttmacher.org

5

Contraception Management

- Contraception as a chronic condition
 - Average age at menarche in U.S. is ~12.5 years old
 - Average of menopause in U.S. ~51 years old
 - "Childbearing age" defined by CDC as 15-44 years old
- Patient's reproductive life plan, preferences, and the safety of methods – may change throughout childbearing years
- Should be re-evaluated and managed appropriately throughout patient's entire reproductive lifetime



6

Contraception Management

- Effectiveness/efficacy
- Safety
- Patient lifestyle & preferences



7

POLL QUESTION

Are you currently certified to prescribe hormonal contraception?

- A. Yes
- B. No
- C. Not applicable

8

Pharmacy access to contraception can help prevent unintended pregnancy

- **Oregon Medicaid**
 - January 2016–December 2017
 - 1,313 RXs for patients in Oregon Medicaid program
 - Estimated to prevent 51 unintended pregnancies
 - Estimated \$1.6 million dollars saved
 - Authors projected New Mexico could save \$2.3 million

Source: Rodriguez, et al. <https://www.ncbi.nlm.nih.gov/pubmed/33083123>

9

Pharmacist prescribing patterns may improve contraception adherence and reach patients in need

- **California, Hawaii, Colorado, and Oregon**
 - January 2019–November 2019
 - 410 patients presenting for contraception
 - Compared to patients seeking contraception from other providers:
 - Lower levels of education
 - Younger
 - More likely to be uninsured
 - Pharmacists were more likely to prescribe 6-month or greater supplies

Source: Rodriguez, et al. <https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2766072>

10

Patients trust pharmacists to help them make decisions about contraception

- **Direct Access Study**
 - 195 patients in Seattle
 - 97.7% “satisfied” or “very satisfied”
 - 97.1% would recommend the pharmacist to a friend
 - 96.6% felt they could ask the pharmacist any questions




Source: Gardner, et al. <https://www.ncbi.nlm.nih.gov/pubmed/34335974>

11

The CDC has identified pharmacy access to contraception as an important service during the COVID-19 pandemic

For more info:

<https://www.cdc.gov/reproductivehealth/contraception/covid-19-family-planning-services.html>



12

Contraception during COVID

- Encourage contactless pick-up (mail, drive-through, curbside)
- Promote OTC products such as emergency contraception and pregnancy tests
- Optimize maximum quantities and refills for birth control prescriptions
- Recommend methods that require less screening (e.g., progestin-only methods)



Source: <https://www.pharmacistimes.com/news/pharmacy-best-practices-for-contactless-care-during-covid-19>

13

POLL QUESTION

Which emergency contraception is most effective for women with a BMI >30?

- A. Plan B
- B. Ella
- C. Copper IUD
- D. None of the above
- E. Not sure



14

Emergency Contraception

Method	Mechanism of Action	How to Use	Notes
Levonorgestrel (Plan B One Step; Next Choice; My Way, etc.)	Prevention of ovulation	1 tablet taken within 72 hours of unprotected intercourse (more effective the earlier it is taken; may use up to 120 hrs but less effective)	- Should be offered to all women using short-acting hormonal contraception to have on hand in the event of missed doses -98-99% effective; less effective in women who are overweight/obese or ≥165 lbs



15

Emergency Contraception

Method	Mechanism of Action	How to Use	Notes
Ulipristal acetate 30 mg (Ella)	Progesterone receptor modulator; inhibits or delays ovulation; may prevent implantation	1 tablet taken within 120 hours (5 days) of unprotected intercourse	~98-99% effective; less effective in obese women



McKesson now has ella[®]. NDC code 73302-456-01, available for purchase at their main DCs.

Additionally, ella[®] is available at the DCs of Cardinal where there is demand for ella[®]. If the Cardinal DC you order from does not have stock, please:

1. Place an order which will trigger the DC to order ella[®] OR
2. Call Cardinal at 855-855-0708 to place the order for ella[®].

16

Emergency Contraception

Method	Mechanism of Action	How to Use	Notes
Copper IUD *not included in prescriptive authority	Prevent fertilization through effect of copper ions on sperm; may interfere with implantation	Place within 5 days of unprotected intercourse	Most effective emergency contraceptive method (1/1000 failure rate) Effective for women who are overweight/obese



17

POLL QUESTION

Have you prescribed or dispensed depo medroxyprogesterone acetate (Depo Provera) for subcutaneous injection?


- A. Yes
- B. No
- C. Not sure / not applicable



18

Depomedroxyprogesterone (DMPA)
150 mg (IM); 104 mg (SQ)


99.8% effective perfect use
 94% effective typical use



Mechanism of Action	How to Use	Notes
Progestin-only method	IM or SQ injection every 3 months (11-15 weeks)	High discontinuation rate compared to other methods (~44-77% in various studies)
Prevention of ovulation Thinning of endometrium		Slow baseline return to fertility (~10 months avg; up to 18+ months)

19

Depo Sub-Q



- “Off label” self-injection
- No generic available (vs. IM formulation)
- Higher rates of continuation with self-administration vs. provider administration
- No difference in pregnancy rates
- Increase in injection site reactions with self-administration; no other difference in adverse effects

Source: <https://gh.bmj.com/content/9/2/004330>

20

POLL QUESTION


Which of the following are considered “LARC”?

- A. Mirena
- B. Nexplanon
- C. Nuvaring
- D. All of the above
- E. A & B only

21

LARC (long-acting reversible contraception)

- **IUD**
 - **Non-hormonal:** Copper IUD (Paragard)
 - **Hormonal:** all contain levonorgestrel (a progestin)
 - Mirena
 - Liletta
 - Kyleena
 - Skyla
- **Implant** – Nexplanon
- >99% effective



22

Pharmacists may not be referring patients for LARC

- **California & Oregon**
 - August 2016–February 2017
 - 381 pharmacists; 2,117 visits
 - Did not identify any referrals for long-acting reversible contraception (LARC)
 - Reasons unknown
 - Women may self-select for pharmacy services
 - Pharmacist counseling may guide women

Source: Lu, et al. <https://www.ncbi.nlm.nih.gov/pubmed/30562475>

23

Pharmacists and LARC


- IUDs and implants are not included in pharmacist prescriptive authority
- LARC use remains low in the U.S. but is increasing
- Half of women surveyed expressed concern about side effects & safety of LARC
- Pharmacists should be prepared to discuss risks and benefits

Sources: Tsai & Roemer. <https://www.ncbi.nlm.nih.gov/pubmed/23535055>
 Burns, et al. <https://www.ncbi.nlm.nih.gov/pubmed/23335025>

24

FDA approvals for extensions of IUD use


- Liletta IUD approved for **6 years** of use in Fall 2019
- Mirena IUD approved for **6 years** of use in August 2020



25

Implant

Mechanism of Action	Notes
Contains 68mg etonogestrel	<ul style="list-style-type: none"> • FDA approved for 3 years; remains effective for 4-5 years • Irregular bleeding is common (~33%) & frequent cause of discontinuation
Thickening of cervical mucus; alteration of endometrium; some anovulatory effects	




Sources: Managing Contraception, Nexplanon prescribing information

26

Copper IUD

Mechanism of Action	Notes
Copper ions inhibit sperm; inflammatory reaction in endometrium	<ul style="list-style-type: none"> • FDA approved for 10 years; effective 12+ years • May increase menstrual bleeding/cramping



Source: <https://www.sciencedirect.com/science/article/pii/S001072492030888>

27

Levonorgestrel (LNG) IUD

Mechanism of Action: Thickening of cervical mucus; alteration of endometrium; some anovulatory effects

Name	Levonorgestrel content	Replace after...years	FDA/ off-label
Mirena ®	52 mg (20 mcg/day)	6 years	7 years
Liletta ®	52 mg (18.6 mcg/day)	6 years	7 years
Kyleena ®	19.5 mg (17.5 mcg/day)	5 years	
Skyla ®	13.5 mg (14 mcg/day)	3 years	

Sources: Mirena, Skyla, Kyleena, and Liletta prescribing information
<https://www.sciencedirect.com/science/article/pii/S001072492030888> / <https://pubmed.ncbi.nlm.nih.gov/2624622/>

28



Recent FDA Approvals


Chat: What new contraceptive methods have patients asked you about in the pharmacy?

29

Behavioral Method

Natural Cycles App

- FDA approved August 2018
- Users track temperature daily and enter readings
- Abstain from intercourse when "use protection" displayed on app
- **Typical use:** ~93% effective




Source: <https://www.fda.gov/news-events/press-announcements/fda-approves-marketing-first-direct-consumer-app-contraceptive-use-at-risk-practices>

30

Barrier Method

Phexxi™

- FDA approved in May 2020
- Typical use: 86% effective**
- Lactic acid, citric acid, and potassium bitartrate 1.8%, 1%, 0.4% vaginal gel
- 5 grams in pre-filled applicator vaginally up to 1 hour before intercourse




Source: Phexxi prescribing information

31

Barrier Method

Phexxi™

- Lowers vaginal pH to reduce sperm motility
- May be used in combination with other vaginal products (e.g., miconazole)
- Some cases (0.36%) of cystitis, pyelonephritis, UTIs in clinical studies



Source: Phexxi prescribing information

32

Progestin-Only Method

Norethindrone 0.35mg
Drospirenone 4mg – Slynd
 Approved June 2019

99.7% effective (perfect use)
 91% effective (typical use)



33

Progestin-Only Method

Mechanism of Action	How to Use	Notes
Primarily works by thickening cervical mucus; ovulation suppressed in ~60% of users	Norethindrone: 1 tablet by mouth every day at the SAME TIME (>3 hours late = "missed dose") No placebo tablets; take continuously	As effective as combined oral contraceptives with correct use Drospirenone has anti-androgenic effects; may be more desirable for patients with acne, PCOS
	Drospirenone: 1 tablet daily (24 hour window) 24 active + 4 inactive tablets	Use drospirenone with caution in hyperkalemia



Sources: Slynd prescribing information; Norethindrone prescribing information; Managing Contraception

34

Combined Hormonal Method

Nuvaring® etonogestrel/ethinyl estradiol 120/15 mcg/day
Annovera® segesterone acetate/ethinyl estradiol 150/13 mcg/day
 Approved August 2018

Nuvaring: >99% effective (perfect use); 91% effective (typical use)
 Annovera (clinical trial): 97.5% effective

Source: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/209627Orig1s100070c.pdf

35

Combined Hormonal Method


Mechanism of Action	How to Use	Notes
Progestone and estrogen combination	Nuvaring 1 ring inserted into the vagina for 3 weeks, then removed for 1 week (off-label); use continuously for 4 weeks, then replace with new ring)	Continuous, steady release of hormones & lowest serum levels of hormones vs. other combined hormonal methods (similar levels in both products)
Prevention of ovulation; thickening of cervical mucus, inhibiting sperm	Annovera 1 ring inserted into vagina for 3 weeks, then removed for 1 week; clean, dry, and store ring during off week; repeat. Can be used for 13 cycles.	Avoid use of oil-based lubricants or vaginal products Annovera has not been adequately evaluated in women with a BMI > 29 Annovera does not require refrigeration

36

Combined Hormonal Method

Twirla™ (120 mcg/d levonorgestrel & 30mcg/d ethinyl estradiol)
 Approved February 2020

99.7% effective (perfect use)
 91% effective (typical use)



Source: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/204027Orig1s40070C.pdf

37

Combined Hormonal Method


Mechanism of Action	How to Use	Notes - Twirla
Progestosterone and estrogen combination	1 patch applied to lower stomach, buttock, or upper torso each week for 3 weeks, then 1 week off	Indicated for women with BMI <30
Prevention of ovulation; thickening of cervical mucus, inhibiting sperm	If patch is detached for >24 hours, use backup method for next 7 days	Reduced effectiveness in BMI ≥25 or weight >92 kg (similar to Xulane)
Estrogen component also helps to stabilize endometrium, decreasing breakthrough bleeding		In clinical trials, 5% of patches detached; patients indicated abdomen was best site for application
		Lower estrogen exposure than Xulane (30mcg vs. 35mcg per day)
		Slightly larger than Xulane; circular vs. square
		Like Xulane, only available in beige

Source: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/204027Orig1s40070C.pdf
 Twirla prescribing information

38

CASES

Discuss what you would recommend for each of the following patients...



39


Case 1: “I know I’m out of time on my IUD, and I cannot get pregnant right now!”

- 33-year-old female
- Married with two children, ages 6 and 8; she is a teacher and reports feeling very stressed by all the online teaching
- Has been using Mirena IUD for the last 5 years; does not have regular periods; satisfied with method
- Medications: Lisinopril 5mg once daily for high blood pressure; BP in pharmacy is 126/78 mmHg
- Presents to the pharmacy asking if you can prescribe birth control because she can’t get in to see her OB/GYN

40

Case 1: “I know I’m out of time on my IUD, and I cannot get pregnant right now!”

Chat: What would you discuss with the patient?



41

Case 2: “I want to use something without hormones.”

- 22-year-old female; student at UNM
- In a monogamous relationship with her partner of two years
- No known medical conditions
- Does not take any medications
- Interested in contraceptive methods, but does not want to take anything that contains hormones

42

Case 2: “I want to use something without hormones.”

Chat: What would you discuss with the patient?



43

Case 3: “Which of these morning-after pills should I buy?”

- 28-year-old female; previously worked as a restaurant server, currently unemployed
- Not in a monogamous relationship, but has been quarantining with a friend with benefits since March, and the condom broke during intercourse last night
- No medication allergies
- Seasonal allergies; takes loratadine as needed
- While chatting with her, she tells you: “I’ve really put on some weight during quarantine! All the stress-eating has me in the 200s now. I’m going on a run after this.”

44

Case 3: “What morning-after pill do you think I should buy?”

Chat: What would you discuss with the patient?



45

Thank you!



Questions?

46